| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Nepafenac | Nepafenac Impurity A | VL360005 | View CAS 2835-77-0 |
| Nepafenac | Nepafenac Inhouse Impurity B | VL360003 | View CAS 78281-61-5 |
| Nepafenac | Nepafenac Inhouse Impurity C | VL360004 | View |
| Nepafenac | Nepafenac Inhouse Impurity D | VL360002 | View |
| Nepafenac | Nepafenac Inhouse Impurity E | VL360001 | View CAS 1246956-18-2 |
| Catalogue No. | VL360001 |
| CAS No. | 1246956-18-2 |
| Molecular Formula | C₁₅H₁₆N₂O₂ |
| Molecular Weight | 256.3 |
| Parent drug | Nepafenac |
| IUPAC Name | 2-Amino-3-(hydroxyphenylmethyl)-benzeneacetamide |
| Synonyms | Nepafenac Hydroxybenzyl Impurity |
| References | Lipiec-Abramska, El?bieta, et al. “Development and Validation of High Performance Liquid Chromatography with a Spectrophotometric Detection Method for the Chemical Purity and Assay of Nepafenac.” Journal of Pharmaceutical and Biomedical Analysis, vol. 91, Mar. 2014, pp. 1–6, https://doi.org/10.1016/j.jpba.2013.12.009.?Di Pascuale, Mario A., et al. “Corneal Melting after Use of Nepafenac in a Patient with Chronic Cystoid Macular Edema after Cataract Surgery.” Eye & Contact Lens: Science & Clinical |
| Status | In-stock |
| ListName | Nepafenac Inhouse Impurity E |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
